Diffucaps® Customized Release Technology

Adare has recently launched a new patient centric dosage solution, the Parvulet TM Technology. The Parvulet TM Technology enables a solid powder or tablet to convert to a semi-solid in the presence of water within thirty seconds. The final dosage is easily administered, as a soft food like texture, ideal for pediatric and geriatric populations (including those with dysphagia).

AdvaTab® Orally Disintegrating Tablets (ODTs) incorporates coated or uncoated drug particles that are uniformly dispersed in a low-moisture, rapidly disintegrating matrix. Each ODT is formulated to achieve an acceptable taste and desired release profile. AdvaTab® technology is ideal for patients who have difficulty swallowing, pediatric, geriatric, and dysphagic patients. This technology can be combined with Microcaps® and Diffucaps® to create IR or controlled-release ODTs.

Microcaps® Taste Masking Technology achieves uniform and efficient coating of drug particles by a combination of coacervation (phase separation) and spray coating to build polymeric membranes of varying porosity and thickness. The completely encapsulated particle allows for a pleasant mouthfeel without an aftertaste. The Microcaps technology can be applied to multiple dosage forms and immediate and modified release profiles.

MMTS TM Multi Mini Tablet System Customized Release Technology combines the simplicity of a tablet formulation with the flexibility of multiparticulate dosage forms with high drug-loading capability. Adare has developed Ultra Microtablets—a smaller standard of tablets targeting diameters in the range of 1.2 mm to even 1.0 mm. The small size facilitates the development of products that can offer multiple drugs or varying release profiles within a single capsule. 

The Optimµm® technology creates microspheres with high drug loading suitable for taste masking, enteric coatings, and extended release oral applications. The technology is capable of producing single- or double-layer particles in a one manufacturing step, lending to cost-effective creation of palatable dosage forms, which mimic traditional tablets, pills, and capsules.  The Optimµm® technology allows for unprecedented control in release rate and dosage form properties.  This technology is ideal for oral small molecules, nutraceuticals, agricultural applications, flavorings, and heat stable molecules.

The Stratµm™ technology, for injectable delivery, allows for precise control of particle size and composition enabling predictable injectable performance, which is critical for self-administration, extended release, and modified release applications with a narrow therapeutic index. Unlike other encapsulation techniques, Stratμm® is capable of producing single- or double-layer particles in a one manufacturing step, lending to creation of next-generation “pulsatile” release formulations or extended release formulations. This technology is ideal for injectable small molecules, proteins, peptides, vaccines, and heat-labile molecules and requires lyophilization.

The Unisun® technology combines the use of encapsulated or free drug, along with a fast-film forming agent, which allows for low-cost, long-acting intratympanic delivery of a therapeutic. The technology allows for less frequent administrations than current therapies and is capable of sustaining drug levels in the inner ear cochlea for weeks. The technology can be used inject and set up highly concentrated depots of a drug and is ideal for small molecules, proteins, peptides, and vaccines

If you’re looking for news, product information and market trends from leading pharma companies, the CPhI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner. 

The Company Showcase profiles offer a library of free to access, downloadable content, including videos and webinars, reports, whitepapers and product brochures, from the Pharma suppliers and service providers you’d look to meet at our events.

Festival of Pharma roundtable discusses how drug delivery formulation and development is focused on hospital-to-home care setting

What kind of enhancement solutions do CDMOs need to offer their pharma clients to address pressing issues such as bioavailability, solubility and stability of their products? A recent CPhI webinar sponsored by Adare Pharmaceuticals delved deep into the issue...

A brief overview presentation describing our company

This Roundtable will feature a high-level panel discussion from industry experts, with numerous opportunities for audience interaction – polls, Q&A and breakout networking sessions. A great opportunity to deep-dive into specific topics, discuss opinions and gather insights from the wider pharma community. For the pharma industry, patients are our most important stakeholders. This roundtable discussion will bring together key industry stakeholders to discuss strategies for improved patient health and outcomes. What are the trends transforming the drug delivery landscape? Putting patient experience at the heart of drug delivery What are the latest approaches for paediatrics, geriatrics, palatability and taste? Delivering value with digital - connected devices, smart solutions and wearables This presentation was originally aired as part of the CPhI Festival of Pharma.

Resource for viewers of the roundtable discussion Patient Centricity: Beyond The Buzz Word at the CPhI Festival of Pharma. Patient Centric Formulation Strategies Adare Overview Problem Statement Swallowing Physiology Regulatory Space New Solution Summary and Remarks

Quick video demonstrating how the technology works.

Interactive brochure describing our company's capabilities

It is a fascinating, exciting and challenging time to be a contract manufacturing and development organisation (CDMO). Increasing drug complexity, growing interest in cell and gene therapies and the COVID-19 pandemic are all having a dramatic impact on the CDMO space. This report examines how CDMOs are reshaping their outsourcing offering to better meet the changing demands of their pharmaceutical customers, and which strategies are being employed to take full advantage of what appears to be an unprecedented growth opportunity for both sides of the partnership.